LIVER DISEASESCREENING STUDY
Alliance Research Institute in Canoga Park is currently seeking participants who may be at an increased risk for developing Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-alcoholic steatohepatitis (NASH).
NAFLD (non-alcoholic fatty liver disease) /Non-alcoholic steatohepatitis (NASH) is the most common liver disease in the United States. The term NAFLD (non-alcoholic fatty liver disease) describes a range of liver disease progression. When fatty liver disease advances to a more severe level of liver injury, it is called nonalcoholic steatohepatitis (NASH) basically scaring of the liver tissue.
Some risk factors for these diseases include:
- Being overweight
- Type 2 Diabetes
- Elevated Lab Results for: blood sugar, or liver enzymes, or HbA1c
This is not a treatment study. There is no study drug or study device. This study will gather information about you and your health to determine your liver health status and potential eligibility for future studies relating to NAFLD/NASH.
Currently there is no medication treatment for this disease and by participating in this research study you will be provided information on the current status of your liver’s health and may have the opportunity to participate in a clinical trial evaluating a treatment for this liver disease.
Participants may be compensated $50 for their time and travel for a 1 to 1.5 hours office visit.